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EGFs (vascular endothelial growth factors) and their receptors (VEGFRs) are a family of regulators of both angiogenesis and lymphangiogenesis, 1 and many preclinical studies, as well as clinical trials have shown their potential in the treatment of ischemic cardiovascular diseases. 2 As hyperlipidemia is a major contributor to atherosclerotic plaque development and coronary heart disease, the role of VEGFs in lipid and lipoprotein metabolism has also gained increasing interest. These studies have focused mainly on VEGF-A showing high expression levels in patients with cardiovascular pathologies, such as hyperlipidemia, atherosclerosis, and myocardial infarction. [3] [4] [5] VEGF-A has been shown to induce triglyceride accumulation in large lipoprotein particles, including VLDL (very low-density lipoprotein), CM (chylomicrons) and their remnants because of lowered LPL (lipoprotein lipase) activity. 6 However, the role of large lipoproteins as a risk factor for the coronary heart disease has been under debate. CMs are large ApoB (apolipoprotein B) containing particles that are assembled from dietary triglycerides and cholesterol in the intestinal enterocytes and carried through lymphatic system to the blood circulation where LPL hydrolyzes triglycerides from the CM particles for the energy needs of peripheral cells. 7 Another VEGF that has been linked to lipid metabolism is VEGF-B, which has high sequence homology to VEGF-A. Whereas VEGF-A binds to VEGFR1 and VEGFR2, VEGF-B functions only through VEGFR1. VEGF-B was reported to increase peripheral tissue fatty acid uptake, as well as adipose tissue function. 8 Furthermore, ectopic lipid accumulation was also linked to blockade of VEGF-C, the main lymphangiogenic factor of the VEGF family that functions mainly through third VEGF receptor, VEGFR3. At the same time, VEGF-C overexpression has been shown to increase liver steatosis. 9 The liver is central to lipid and lipoprotein metabolism as CRs (CM remnants) are internalized by hepatocytes via LDLR (low-density lipoprotein receptor), LRP (LDLR related protein), and HSPGs (heparan sulfate proteoglycans) that recognize apolipoproteins on the surface of the remnant particles. 10 Large cohort data analysis has revealed an association between elevated triglyceride levels and cardiovascular events, 11 emphasizing the significance of CMs and CRs in cardiovascular diseases.
VEGF-D, a secreted glycoprotein, is the newest member of the VEGF family that as of yet has not been linked to lipid metabolism. VEGF-D is produced in several adult tissues, including lung, skin heart, skeletal muscle, colon, and small intestine. 12 VEGF-D promotes lymphangiogenesis and angiogenesis by binding to its endothelial cell receptors VEGFR2 and VEGFR3, 12 as well as to coreceptors NRP1 (neuropilin 1) and NRP2 and heparin. 13 Interestingly, mouse VEGF-D has been suggested to be a VEGFR3 specific ligand and capable of inducing only lymphangiogenesis. 14 However, a later study indicated that mouse VEGF-D has also angiogenic potential when delivered with gene transfer vectors. 15 Short, angiogenic form of VEGF-D has been successfully used in several preclinical studies [16] [17] [18] and in a phase I/IIa phase clinical trial 19 to induce therapeutical angiogenesis. In this study, we hypothesized that blockade of VEGF-D could reveal alterations in lipoprotein metabolism and atherogenesis. Hence ) had significantly increased plasma cholesterol and triglyceride levels on Western-type high-fat diet. Our data revealed that the deletion of VEGF-D leads to the downregulation of a major hepatic HSPG, SDC1 (syndecan 1), and consequently to the accumulation of large lipoprotein particles in the plasma. These findings indicate that VEGF-D is an important previously unrecognized modifier of lipoprotein metabolism.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on request. RNA-sequencing data has been made publicly available at the NCBI GEO database and can be accessed through GEO accession number GSE108959.
Experimental Animals
Mice deficient of LDLR and expressing only ApoB100 (LDLR −/− ApoB 100/100 ) 20 on C57Bl/6 background (The Jackson Laboratory) were crossbred with VEGF-D 14 deficient mice on a C57Bl/6 background. Male VEGF-D knockout and LDLR −/− ApoB 100/100 control mice were fed a Western-type high-fat diet (TD.88137; Envigo) from 4 to 5 months and 12 months of age for 6 or 12 weeks, respectively. Murine models display sexual dimorphism in many hepatic genes involved in lipid metabolism and atherogenesis. 21 To avoid sex-related confounding factors, we only studied male mice. Mice were anesthetized with isoflurane (4% induction, 2% maintenance) for intravenous injections and imaging. All animal procedures were approved by the National Animal Experiment Board in Finland and were performed in accordance to the guidelines of the Experimental Animal Committee of the University of Eastern Finland. Atherosclerotic studies were performed according to the American Heart Association guidelines.
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Clinical Chemistry and Lipoprotein Profiling
Blood plasma and serum samples were collected after overnight fastening from tail vein or heart puncture. Plasma triglyceride, total cholesterol, and ALAT (alanine aminotransferase) values were determined by Movet Oy diagnostic laboratory (Kuopio, Finland). Cholesterol in VLDL fractions was measured with the Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific). Blood glucose levels were measured using Ascencia Elite XL glucose meter (Bayer). Serum free fatty acid (FFA) levels were measured with colorimetric FFA Quantitation Kit (Sigma). For the analysis of lipoprotein profiles, pooled plasma samples (n=4/group) were fractionated by fast-performance liquid chromatography as described. 23, 24 Lipoprotein fractionation analysis was performed by the LipoSEARCH analytical service (Skylight Biotech, Inc). Total particle sizes were measured from plasma samples with ZetaSizer Nano (Malvern Instruments).
LPL and HL Activity
For the measurement of LPL and HL (hepatic lipase) activity, mice were fasted overnight, and food was returned for 6 hours. Mice were given an intravenous heparin bolus (100 U/kg; Heparin Leo), and plasma samples were collected after 10 minutes. Lipase activities were measured using a radiometric assay with a synthetic [14C]triolein substrate emulsified in the presence of 5% (w/v) gum Arabic. 25, 26 To distinguish between HL and LPL activities, HL lipolytic activity was measured in the presence of high salt (1 M NaCl).
Apolipoproteins in TriglycerideRich Lipoprotein Particles
Apolipoproteins were analyzed as previously described. 27 In brief, lipoprotein fractions from pooled plasma samples (100 μL/mouse, n=4/group) were separated by buoyant density ultracentrifugation (6 hours at 38 000 rpm). The top 50 μL fraction containing VLDL and CR (δ <1.006 g/mL) was used for analysis. TRLs (triglyceride-rich lipoprotein) were separated by SDS-PAGE on 4% to 12% Bis-Tris gradient gels (NuPage, Invitrogen 
Lipid Absorption and Retinol Excursion
To measure intestinal lipid absorption, overnight-fasted mice received first an intravenous bolus of Tyloxapol (0.5 mg/g; Acros Organics) and 30 
Clearance of CM/CRs
Donor mice were fasted for 5 hours and subjected to oral corn oil gavage (200 μL/mouse) containing 5 μCi [11,12-3H]retinol (SigmaAldrich). Blood was collected 3 hours after gavage by cardiac puncture.
[3H]CM/CRs were isolated by buoyant density ultracentrifugation. 27 After overnight fasting, receiver mice were intravenously injected with [3H]CM/CRs (≈7100 cpm/mouse). Blood samples were taken from tail vein at 1, 5, 15, and 30 minutes. Radioactivity in plasma samples was determined by liquid scintillation counter and calculated as a percentage of [3H] activity remaining in the blood 1 minute after the injection.
Hepatic VLDL-Triglyceride Secretion
To analyze the production of VLDL, mice were fasted overnight and given an intravenous bolus of Tyloxapol (0.5 mg/g; Acros Organics) to block lipolysis. Plasma samples were collected 1, 30, 60, 90, and 120 minutes after the injection and triglycerides were measured.
LDL Turnover
To analyze LDL turnover, human LDL was iodinated with [125I] as previously described. 29 Mice were injected with 100 μL of [125I]LDL intravenously, and blood samples were collected at the time points 3 minutes and 0.5, 1, 3, 6, 12, 24, and 36 hours after the injection. Radioactivity was measured using a gamma counter (Gammamaster 1277, Wallac Oy) and calculated as a percentage of [125I]LDL activity remaining in the blood 1 minute after the injection.
Real-Time Quantitative Polymerase Chain Reaction and RNA-Sequencing
Tissue samples were homogenized (Precellys 24, Bertin Instruments) and total RNA was isolated using RNeasy Lipid Tissue Mini Kit or RNeasy Mini Kit (Qiagen). Quantitative measurements of mRNAs were performed with StepOnePlus Real-Time Polymerase Chain Reaction System (Thermo Fisher Scientific). For RNA-Sequencing, libraries were prepared as described. 30 Processing of sequencing reads was carried out as described, 31 except that data was mapped to mouse genome (version mm9) using tophat v2.0.7. 32 Differentially expressed genes were identified using edgeR 33 by using thresholds of false discovery rate <0.05, reads per kb per million reads >0.5 and log fold change >0.585. For gene ontology analysis, Ingenuity Pathway Analysis and Gene Ontology Enrichment analysis were used.
Protein Extraction and Western Blotting
Proteins were extracted using T-PER Tissue Protein Extraction Reagent (Thermo Fisher Scientific). Total protein content was determined using BCA (bicinchoninic acid) protein assay (Pierce, Thermo Fisher Scientific). Twenty to 50 µg of protein was separated on Mini-PROTEAN TGX Stain-Free gels (Bio-Rad) and transferred to nitrocellulose membrane (Bio-Rad). The membrane was incubated overnight at 4°C with primary antibodies: CD138 (BD Biosciences), Akt (AKT serine/threonine kinase 1), pAKT (phospho-Akt), Erk1/2 (extracellular signal-regulated kinase), phospho-Erk1/2, mTOR (mechanistic target of rapamycin), phosphor-mTOR, VEGFR2 (Cell Signaling), and VEGFR3 (Thermo Fisher Scientific). Stain-Free gels were UV activated for 2.5 minutes before blotting, and total protein amount was measured with ChemiDox XRS (Bio-Rad) before enhanced chemiluminescence detection. Specific bands were normalized to total protein using the ImageLab software (Bio-Rad).
Histochemical Analyses
Mice were sacrificed with CO2 and perfused through left ventricle with PBS. Tissue samples were collected to 4% paraformaldehyde in PBS for overnight fixation and stored in 15% sucrose in H 2 O. Aortas were opened longitudinally, pinned out, and stained with Oilred O for en face evaluation. 23 Other tissue samples were embedded in paraffin and cut for 4 µm sections for hematoxylin-eosin and immunohistochemical stainings. After overnight blocking, tissue sections were incubated with CD138 (BD Biosciences) or F4/80 (Serotec) antibody in Dako antibody diluent (Agilent). The sections were then incubated with biotinylated secondary antibodies (Vector Laboratories), VECTASTAIN Elite ABC-HRP, and DAB Peroxidase (Vector Laboratories). Tissue sections were imaged with Eclipse Ni-E microscope (Nikon). Images were analyzed with ImageJ (National Institutes of Health). The size of atherosclerotic lesions was measured from 7 tissue sections covering the whole brachiocephalic artery, as well as from a tissue section at the level of aortic valve cusps in the aortic root. Lesion areas are presented as a percentage from the intima.
Statistics
Statistical analyses were performed with GraphPad Prism v5.03 (GraphPad Software). The normality of the data was tested with the Kolmogorov-Smirnov test and variance with F test. Significance was tested using Student t test or 2-way ANOVA with Bonferroni multiple comparison post-test, as well as repeated measures ANOVA followed by Bonferroni post hoc test. Results are expressed as mean±SEM, and differences were considered statistically significant at *P <0.05, **P <0.01, ***P <0.001.
Results
VEGF-D Regulates CM and TRL Metabolism
To determine the effects of VEGF-D deficiency on lipoprotein metabolism, we bred Vegfd knockout mice into the LDLR ) presented hypertriglyceridemia on a chow diet (3.2 mmol/L), which worsened after starting Western diet reaching 6.6 mmol/L at week 6 and finally declined to 3.4 mmol/L at 12 weeks resulting in visibly milky plasma ( Figures 1A and 1B) . Already after 2 weeks on Western diet, plasma cholesterol levels in VEGF-D knockout mice were significantly elevated compared with the control mice (41.1 mmol/l versus 27.7 mmol/L, respectively; Figure 1C) . Furthermore, cholesterol levels rose on Western diet reaching 62.6 mmol/L in VEGF-D knockout mice compared with 42.7 mmol/L in the control mice at 12 weeks ( Figure 1C) . Similarly, cholesterol and triglyceride levels in 12-month-old VEGF-D knockout mice were significantly increased on Western diet ( Figure IA and IB in the online-only Data Supplement).
Next, we determined triglyceride and cholesterol levels within different lipoprotein fractions to define the main culprit of hyperlipidemia. Fast protein liquid chromatography lipoprotein profiling revealed triglyceride and cholesterol elevation in elution fractions corresponding to CMs and VLDL ( Figure 1D ). Further analysis using gel-filtration high-performance liquid chromatography verified that triglyceride and cholesterol levels were significantly increased in CMs, CRs, and VLDL fractions in VEGF-D knockout mice ( Figure 1E and 1F) indicating accumulation of these large lipoprotein particles. Total plasma particle size distribution analysis also confirmed a shift towards larger particles in VEGF-D knockout mice (mean diameter of 100-500 nm versus 20-80 nm in the control mice) ( Figure 1G ). To analyze these particles further, TRL fraction including CMs, CRs, and VLDLs B, Measurements of plasma triglyceride levels (n=8-11/group). C, Measurements of plasma cholesterol levels (n=8-11/group). D, Plasma lipoprotein profiles analyzed by fast protein liquid chromatography (n=4/pool). E and F, Detailed plasma triglyceride (TG; E) and cholesterol (F) distribution analyzed by gel-filtration high-performance liquid chromatography (n=4/group). G, Whole plasma particle distribution (n=4/group). H and I, TG concentration (H) and particle size (I) of isolated TRLs (triglyceride-rich lipoprotein; n=4/pool). J, Western blot analysis of TRL apolipoproteins (n=4/pool). K and L, Measurements of LPL (lipoprotein lipase; K) and HL (hepatic lipase; L) activity (n=4-6/group). M, mRNA expression of LPL and GPIHBP1 (glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1; n=6/group). N, Serum free fatty acid (FFA) analysis (n=3-4/group). Values are mean±SEM. ***P<0.001; **P<0.01; *P<0.05 compared with control mice. Statistical analyses were performed using Student t test or repeated measures ANOVA followed by Bonferroni post hoc test. CE indicates cholesteryl ester; CM, chylomicron; CR, chylomicron remnant; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very low-density lipoprotein.
was extracted with ultracentrifugation. Triglyceride levels were significantly increased in TRLs in VEGF-D knockout mice ( Figure 1H) , and the ratio of triglyceride concentration to cholesterol concentration was increased indicating larger particle size ( Figure 1I ). Western blot analysis for TRLs revealed that the levels of ApoB100, ApoE, and ApoC-III were increased in VEGF-D knockout mice ( Figure 1J ). These analyses indicate that VEGF-D knockout mice accumulate large lipoproteins enriched for ApoE and ApoC-III.
To assess whether inefficient lipolysis was responsible for the accumulation of large lipoproteins in VEGF-D knockout mice, the expression and activity of LPL and HL were measured ( Figure 1K and 1 L) . VEGF-D knockout mice showed no changes in LPL or HL activity indicating that the increases in triglyceride and cholesterol levels in CM particles were not caused by changes in lipase activity. Also, mRNA expression levels of LPL and GPIHBP1 (Glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1) in cardiac muscle remained unaltered ( Figure 1M ). However, VEGF-D knockout mice had almost 5-fold higher fasting FFA levels than control mice (0.34 mmol/L versus 1.65 mmol/L, respectively; Figure 1N 
VEGF-D Knockout Mice Do Not Display Increased Atherosclerosis
To assess the impact of the lipid phenotype on cardiovascular risk, we evaluated the development of atherosclerosis in VEGF-D knockout mice at 4-5 (young) and 12 (old) months of age via en face staining of the whole aortas and hematoxylin and eosin staining of aortic roots and brachiocephalic arteries on both chow and Western diets. Although both young and old VEGF-D knockout mice displayed markedly elevated plasma cholesterol and triglyceride levels ( Figure 1A -1C, Figure IA and IB in the online-only Data Supplement), no significant increases in lesion sizes were detected compared with the control mice (Figures 2A-2C ). On the contrary, young chow-fed VEGF-D knockout mice had significantly smaller atherosclerotic lesions in the aortic root analysis (Figures 2A  and 2D ), whereas no differences were found in advanced lesions of young mice after 12 weeks on Western diet ( Figures 2B and 2E) . Furthermore, old VEGF-D knockout mice after 6 weeks on Western diet displayed significantly smaller lesions in the aorta en face preparation than controls ( Figures 2C and 2F) . These results indicate that the development of atherosclerotic is not accelerated in VEGF-D knockout mice despite hypercholesterolemia. Furthermore, both groups exhibited similar heart parameters measured with echocardiography ( Figure III in the online-only Data Supplement).
VEGF-D Regulates CR Clearance Rather Than Intestinal Lipid Absorption
To measure if hyperlipidemia inflicted by VEGF-D deficiency is secondary to increased dietary lipid absorption and CM secretion, we administered a bolus of [ 3 H]triolein in olive oil by oral gavage and the intestinal uptake and secretion into the circulation of the tracer was measured in plasma at various time points ( Figure 3A ). In addition, the tissue accumulation of the tracer 3 hours after bolus was quantified ( Figure 3B ). VEGF-D knockout mice had normal lipid absorption and secretion but less accumulation of [3H]triolein in the liver compared with controls. Both groups exhibited equal uptake of the tracer to peripheral tissues, which confirmed uniform lipase function between the groups. Whereas triolein is hydrolyzed from CM particles to extrahepatic tissues, retinol is transported to liver and thereby enables to study the hepatic clearance of intestine- CM (chylomicron)/CRs (chylomicron remnants) was measured from plasma after intravenous injection (n=4/group). H and I, LDL turnover was measured after intravenous injection of [125I]LDL (low-density lipoprotein; n=6/group). J and K, Hepatic VLDL (very low-density lipoprotein) production was measured after intravenous injection of Tyloxapol (n=5-6/group). Values are mean±SEM. ***P<0.001; **P<0.01; *P <0.05. Statistical analyses were performed using 1-way or 2-way or repeated measures ANOVA followed by Bonferroni post hoc test or 2-tailed Student t test. AUC indicates area under the curve; TG, triglyceride; and WAT, white adipose tissue.
To evaluate if the endogenous lipoprotein production in the liver is altered in VEGF-D knockout mice, we analyzed VLDL production by giving a bolus of Tyloxapol, a compound that prevents lipolysis, and measured plasma triglyceride levels ( Figure 3J and 3K ). In the first 3 time points, change in plasma triglycerides was similar between both groups. However, triglyceride production accelerated significantly in VEGF-D knockout mice after 60 minutes confirming accumulation of triglyceride-rich particles in plasma. This increase could account for the rise of triglyceride levels in VLDL fraction ( Figure 1E ) but does not explain the accumulation of CMs and their remnants or decreased hepatic CR uptake.
VEGF-D Controls Genes Related to Inflammation and Lipid Metabolism in Liver
To understand the mechanisms leading to accumulation of CR, differences in the expression levels of hepatic mRNAs were assessed with deep sequencing. Compared with the control mice, a total of 683 genes were differentially expressed in VEGF-D knockout mice ( Figure 4A ), from which 424 were upregulated and 259 downregulated ( Figure 4B ). Gene ontology analysis of biological processes revealed that most of the activated pathways in VEGF-D knockout mice were related to inflammatory responses, immune cell trafficking, and cell adhesion ( Figure 4C ), whereas downregulated pathways were involved in lipid metabolism ( Figure 4D ). Downregulated genes that are linked to lipid metabolism pathways included monoacylglycerol O-acyltransferase 1 (MOGAT1) and 1-Acylglycerol-3-phosphate O-acyltransferase 1 (AGPAT4) indicating lower TG production, as well as Cytochrome P450 family members, which have been shown to be related to steroid, fatty acid (FA), and cholesterol metabolism. Also, peroxisomal β-oxidation pathway genes were downregulated ( Figure 4D) . Genes regulating cholesterol synthesis were unaltered but important CM apolipoproteins ApoC-II and ApoA-IV were highly upregulated ( Figure 4E ). In addition, FA transport proteins and perilipins were downregulated indicating lower liver FA uptake and storage which is in agreement with reduced hepatic lipid uptake and high serum FFA levels ( Figure 4E ).
Blockade of VEGF-D Leads to Reduced Hepatic SDC1 Expression
The accumulation and reduced hepatic uptake of CRs in VEGF-D knockout mice suggested that VEGF-D could regulate the expression of hepatic lipoprotein receptors. Previous studies have shown that HSPGs and LDLR dominate the remnant clearance under fasting and postprandial conditions, but LRP1 contributes significantly when LDLR is absent. 34 Hepatic RNAsequencing showed that both groups expressed similar levels of LRP1 and SCARB1 or SR-BI (scavenger receptor class B type 1), but VEGF-D knockout mice had significantly reduced levels of SDC1, the most notable HSPG ( Figure 4E ). To confirm these results, we performed real-time quantitative polymerase chain reaction analysis of SDC1 and NDST1 (N-deacetylase N-sulfotransferase 1), a heparan sulfate biosynthetic enzyme ( Figure 5A ). VEGF-D knockouts exhibited significantly reduced expression of both SDC1 and NDST1. In addition, immunohistochemical staining revealed decreased and nonhomogeneous expression of SDC1 in the sinusoidal surface of hepatocytes in VEGF-D knockout mice ( Figure 5B ). These changes suggest that VEGF-D knockout can alter the expression of NDST1 and SDC1, which could explain the delayed CR catabolism and accumulation of ApoC-III and ApoE enriched large lipoproteins. 27 To further analyze SDC1 expression and the major VEGFR-signaling cascades, Western Blot analysis was performed for SDC1, VEGFRs, ERK, mTOR, and AKT ( Figure 5C ). Western Blot analysis revealed that especially the protein expression of SDC1 was significantly reduced in the livers of VEGF-D knockout mice ( Figure 5D ). Also, the pAKT was decreased indicating downregulation of AKT pathway downstream of VEGFR3 ( Figure 5E ). To gain further mechanistic insight on how inhibition of VEGF-D affects hepatic receptor signaling, we extracted the expression profile of VEGF family members from the RNA-sequencing data ( Figure 5F ). Interestingly, VEGF-A and NRP1 mRNA levels were significantly increased in VEGF-D knockout mice indicating that VEGF-A signaling would compensate for the deletion of VEGF-D. Also, VEGF-C levels were increased suggesting that it would substitute VEGF-D as VEGFR3 ligand. Statistical analyses were performed using 2-tailed Student t test. ERK indicates extracellular signal-regulated kinase; KO, knockout; mTOR, mechanistic target of rapamycin; NRP, neuropilin; p-ERK, phospho-extracellular signal-regulated kinase; p-mTOR, phospho-mechanistic target of rapamycin; RPLP0, ribosomal protein lateral stalk subunit P0.
Discussion
In the present study, we have thoroughly characterized the effects of VEGF-D deficiency on lipoprotein metabolism and atherosclerosis. As a genetic background, we used LDLR −/− ApoB 100/100 mice, which are designed to mimic human lipoprotein profile and apolipoprotein distribution promoting atherosclerotic plaque development. 20 Our unexpected findings show that VEGF-D deficiency on a hyperlipidemic background leads to significantly elevated cholesterol and triglyceride levels but not to increased atherogenesis. Size distribution and hepatic uptake studies confirmed a delayed clearance of large CR particles.
To clarify mechanisms leading to markedly increased plasma lipid levels in VEGF-D knockout mice, we first assessed the functionality of liver in the regulation of lipoprotein metabolism. We show that the hepatic accumulation of radiolabeled intestinal-derived retinol was significantly decreased compared with the controls suggesting that VEGF-D deficiency affects especially the clearance of large intestine-derived CMs. This was further supported by the observation that ApoC-III and ApoErich large lipoproteins accumulated in VEGF-D knockout mice. After lipolysis, CRs have to first pass through the fenestrated endothelium of the liver sinusoids and become sequestered in the perisinusoidal space of Disse before being cleared by hepatic endocytic receptors. 10, 35 Defective hepatic clearance of CRs can lead to high plasma cholesterol and triglyceride levels in conditions like type III hyperlipoproteinemia caused by mutated ApoE. 36 Since LDLR was not present in VEGF-D knockout mice, other factors, such as LRP1 and SDC1, predominate as major receptors for ApoB containing lipoproteins. 37 In previous studies, the deletion of SDC1 was shown to reduce hepatic uptake of TRLs and increase plasma triglyceride levels leading to an accumulation of ApoC-III and ApoE enriched TRLs, especially when LDLR was absent. 34 Here we show that the expression of LRP1 was unchanged in the livers of VEGF-D knockout mice, but both SDC1 and its cofactor NDST1 were significantly downregulated. Immunohistochemical analysis revealed that the sinusoidal surface of hepatocytes throughout the liver expressed SDC1 in control mice, whereas the expression was downregulated and nonhomogeneous in VEGF-D knockout livers. VEGF-D has been shown to phosphorylate AKT via VEGFR3 activation in vitro, 38 which is consistent with our results from the liver tissue in vivo. VEGF-D deficiency led to decreased phosphorylation of AKT, downstream of VEGFR3, and possibly contributed to lower SDC1 expression in the sinusoidal surface of hepatocytes, consequently manifesting in reduced hepatic CR uptake.
Hyperlipidemia is usually associated with an increased risk of premature atherosclerosis. Surprisingly, VEGF-D knockout mice did not exhibit increased atherosclerotic lesion development. Our data demonstrate that cholesterol and triglycerides in VEGF-D knockout mice are carried in large lipoprotein particles that cannot easily penetrate through the vascular endothelium. 39 Lipoprotein disorders characterized by accumulation of large lipoprotein particles, such as in LPL-deficiency, do not have an increased risk of developing atherosclerosis because of the lipoprotein particle size limitation. 7 Lipoprotein profile analysis revealed that VEGF-D knockout mice did not show elevated cholesterol levels in LDL particles, the main culprit of atherosclerosis. LDL is considered to be the most atherogenic lipoprotein, mainly because of its ability to easily penetrate the endothelial barrier and be retained within the intima leading to plaque development.
Our study with VEGF-D knockout mice highlights clear similarities with a transgenic mouse model with a soluble decoy VEGFR3 expression in the skin keratinocytes, which led to fluid retention, increased total plasma cholesterol levels and accelerated atherogenesis. 23 Downregulation of VEGFR3 signaling leads to lymphatic dysfunction, which was considered to be the primary reason for hyperlipidemia and increased atherogenesis in these mice. However, VEGF-D knockout mice do not exhibit similar lymphatic phenotype suggesting alternative mechanisms. Interestingly, the lipid phenotype of the VEGF-D knockout mice seems also to resemble the findings from sirolimus-treated patients with lymphangioleiomyomatosis, a rare lung disease characterized by abnormal growth of smooth muscle cells in lungs, lymphatic system, and kidney. 40 The main culprit of lymphangioleiomyomatosis is increased VEGF-D expression, 41 and the disease is treated with m-TORC1 (mTOR complex 1) inhibitor sirolimus. 42 Patients treated with sirolimus have lower VEGF-D levels but surprisingly also hypertriglyceridemia, hypercholesterolemia, and increased levels of plasma FFAs but normal LPL activity. 43 Hyperlipidemia has been suggested to result from an increased VLDL production in these patients but molecular mechanisms have remained unclear. 43 Interestingly, SDC1 was downregulated in the adipose tissue of rats treated with sirolimus, 44 which further supports the connection between VEGF-D and SDC1 identified in the present study.
Patients with ischemic cardiovascular disease have variable serum VEGF-D levels, 19 but the role of circulating VEGF-D in the disease development has not been determined. Here, we report a novel finding that VEGF-D deficiency leads to markedly increased cholesterol and triglyceride accumulation in CM and CR particles and reduced hepatic uptake of CRs in atherosclerotic mice. Mechanistically, the deletion of VEGF-D resulted in the downregulation of SDC1, one of the key HSPGs responsible for hepatic clearance of ApoE and ApoA-V containing lipoproteins. However, VEGF-D knockout mice did not show increased atherosclerosis. Therefore, these results raise an intriguing question whether VEGF-D levels of familial hypercholesterolemia patients should be screened to identify individuals who may be at high risk of elevated CRs potentially affected by their serum VEGF-D levels. We conclude that VEGF-D is an important modifier of lipoprotein metabolism in mice and that VEGF-D is essential especially for the metabolism and hepatic uptake of CRs.
